Prediction Case File
YouTubeEvaluation Complete

Ranking The Magnificent 7 Stocks! Best To Worst

5 extracted signals · 5 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
02 Aug 2026, 13:01 UTC
Recorded by Tahlil Plus
02 Aug 2026, 13:12 UTC
Video preview for Ranking The Magnificent 7 Stocks! Best To Worst
Source overview

AI-generated source summary

The analysis ranks several tech stocks based on their potential for growth and risk-reward. Meta (META) is ranked highest due to its perceived undervaluation and potential for future monetization of its platforms, despite recent earnings misses. NVIDIA (NVDA) is ranked highly due to its strong revenue growth and favorable P/E ratio, seen as attractive even with its recent gains. Microsoft (MSFT) is ranked as overvalued, trading at a high P/E ratio with slower growth compared to peers. Amazon (AMZN) is seen as a solid contender due to its consistent growth in AWS and other segments, despite its high P/E ratio. Google (GOOGL) is considered fully priced but showing strong recovery and growth in its cloud segment. Apple (AAPL) is ranked lower due to high valuation and perceived lack of innovation compared to its peers, making it less attractive for short-term investors but potentially still a long-term hold. Tesla (TSLA) is ranked lowest, with the analyst not understanding its business model or market position. The P/E ratios and growth forecasts were considered in the ranking, with a focus on companies that reinvest in themselves for long-term growth.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
5
Extracted from this source
Open
0
Still being tracked
Successful
5
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
100%
5 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    5 eligible signals linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  7. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail